News Sentiment

EWTX sentiment intelligence

Edgewise Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 61 Balanced news tone 67 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 45.41 Week of 10 Jul 2026
Weighted tone 61/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 59

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+14.8% over one week, +30.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Boulder biotech unloads muscular dystrophy drug for up to $2.65 billion

Market Reaction

Price moving ahead of tone

71/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction 14.8% Price confirming higher
Trend fit Trend active 30.4% over four weeks
Fair value 124.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 29
Neutral 33
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 59
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 7
Investing.com 5
PR Newswire 4
Moomoo 4
MT Newswires 4
Investing.com Canada 4
TradingView 3

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 13
Analyst action 9
Deals and strategy 4
Balance sheet 3
Regulatory and legal 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 67
The Business Journals Direct company coverage

Boulder biotech unloads muscular dystrophy drug for up to $2.65 billion

Boulder-based Edgewise Therapeutics has sold its muscular dystrophy drug for an upfront payment of $1.55 billion, with the potential to receive an additional $1.1 billion if certain regulatory and commercial milestones are met. The company went public on Nasdaq in 2021.

Tone
Positive 82/100
Event
Regulatory and legal
Published
13 Jul 2026 21:14
Source
The Business Journals
Investing.com Direct company coverage

Edgewise completes sale of sevasemten to Servier for $2.65B

Edgewise Therapeutics Inc. has completed the sale of sevasemten and its muscular dystrophy business to Servier for $2.65 billion, including $1.55 billion upfront and up to $1.1 billion in milestone payments. This transaction shifts Edgewise's strategic focus to cardiovascular dis

Tone
Positive 74/100
Event
Market update
Published
13 Jul 2026 16:39
Source
Investing.com
citybiz Direct company coverage

Edgewise Therapeutics Completes Up to $2.65 Billion Sevasemten Sale to Focus on Cardiovascular Pipeline

Edgewise Therapeutics Inc. has completed the sale of sevasemten and its muscular dystrophy business to Servier for up to $2.65 billion, including $1.55 billion upfront. This strategic move allows Edgewise to focus entirely on its cardiovascular pipeline, advancing treatments for

Tone
Positive 71/100
Event
Market update
Published
13 Jul 2026 14:11
Source
citybiz
grafa.com Direct company coverage

Edgewise sells sevasemten business for $1.55 billion

Edgewise Therapeutics has sold its sevasemten and muscular dystrophy business to Servier for an upfront cash payment of $1.55 billion and up to $1.1 billion in potential milestones. This transaction allows Edgewise to focus its resources on its cardiovascular pipeline, including

Tone
Positive 65/100
Event
Balance sheet
Published
13 Jul 2026 13:16
Source
grafa.com
Stock Titan Direct company coverage

[8-K] Edgewise Therapeutics, Inc. Reports Material Event

Edgewise Therapeutics, Inc. announced the completion of the sale of its sevasemten compound and muscular dystrophy program to Servier Pharmaceuticals and Les Laboratoires Servier for up to $2.65 billion, including $1.55 billion upfront. This transaction strengthens Edgewise's bal

Tone
Positive 77/100
Event
Market update
Published
13 Jul 2026 12:14
Source
Stock Titan
PR Newswire Direct company coverage

Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business

Servier has finalized its acquisition of Edgewise Therapeutics' muscular dystrophy business for up to $2.65 billion, which includes an upfront payment of $1.55 billion and up to $1.1 billion in milestone payments. This acquisition significantly enhances Servier's rare neurology p

Tone
Positive 70/100
Event
Deals and strategy
Published
13 Jul 2026 12:14
Source
PR Newswire
Stock Titan Direct company coverage

Muscular dystrophy drug sevasemten drives Servier’s $2.65B Edgewise buy

Servier has completed the acquisition of Edgewise Therapeutics' muscular dystrophy business for up to $2.65 billion, including an upfront payment of $1.55 billion and potential milestone payments. This deal secures sevasemten, a late-stage therapy for Becker muscular dystrophy an

Tone
Positive 74/100
Event
Deals and strategy
Published
13 Jul 2026 12:11
Source
Stock Titan
PR Newswire Direct company coverage

Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

Edgewise Therapeutics has announced the completion of the sale of its muscular dystrophy business, including sevasemten, to Servier for up to $2.65 billion. This transaction provides Edgewise with $1.55 billion in upfront cash and up to $1.1 billion in milestone payments, signifi

Tone
Positive 95/100
Event
Balance sheet
Published
13 Jul 2026 12:11
Source
PR Newswire
Kavout | AI Direct company coverage

Is Edgewise Therapeutics (EWTX) on the Cusp of a Breakthrough Year

Edgewise Therapeutics (EWTX) is approaching a potentially transformative 2026 with critical clinical trial data readouts for its lead candidates, sevasemten and EDG-7500, targeting rare muscle and cardiac diseases. Investors are closely watching the Phase 3 data for sevasemten in

Tone
Positive 66/100
Event
Market update
Published
11 Jul 2026 11:10
Source
Kavout | AI
Trefis Direct company coverage

Edgewise Therapeutics Stock Rides A 5-Day Winning Streak To A 23% Gain

Edgewise Therapeutics (EWTX) stock has experienced a significant 5-day winning streak, gaining 23.5% and adding $985 million to its market value, now at $5.2 billion. Despite this surge, its valuation metrics, such as a P/E of -29.4 compared to the S&P 500 median of 24.4, suggest

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 11:41
Source
Trefis
Moomoo Direct company coverage

Oppenheimer Initiates Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $51

Oppenheimer has initiated coverage on Edgewise Therapeutics (EWTX.US) with a "Buy" rating. The firm has set a price target of $51 for the company's stock, indicating a positive outlook for its future performance. This suggests Oppenheimer believes Edgewise Therapeutics has signif

Tone
Positive 86/100
Event
Analyst action
Published
09 Jul 2026 22:41
Source
Moomoo
Investing.com Direct company coverage

Oppenheimer initiates Edgewise Therapeutics stock with outperform rating

Oppenheimer has initiated coverage on Edgewise Therapeutics Inc. (NASDAQ:EWTX) with an Outperform rating and a price target of $51.00. The company, a clinical-stage biopharmaceutical firm, is developing therapies for hypertrophic cardiomyopathy and is fully funded through commerc

Tone
Positive 80/100
Event
Analyst action
Published
09 Jul 2026 12:10
Source
Investing.com
TradingView Direct company coverage

Price to book forward of Edgewise Therapeutics, Inc. – NASDAQ:EWTX

This article provides financial information for Edgewise Therapeutics, Inc. (NASDAQ: EWTX), specifically focusing on its forward price-to-book ratio. The content appears to be a stub or a data placeholder, indicating where this financial metric would be displayed. It shows that t

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 18:09
Source
TradingView
Investing.com Direct company coverage

Edgewise Therapeutics stock hits all-time high at 43.96 USD

Edgewise Therapeutics stock reached an all-time high of $43.96, currently trading at $44.17 with a market capitalization of $4.66 billion. The stock has seen a 231% increase over the past year, driven by strong investor confidence and positive analyst updates. Several firms like

Tone
Positive 80/100
Event
Analyst action
Published
08 Jul 2026 17:09
Source
Investing.com
Investing.com Canada Direct company coverage

Edgewise Therapeutics stock hits all-time high at 43.96 USD By Investing.com

Edgewise Therapeutics Inc. (EWTX) stock reached an all-time high of $43.96, currently trading at $44.17 with a market capitalization of $4.66 billion. The stock has increased by 231% over the past year, reflecting strong investor confidence despite an InvestingPro suggestion that

Tone
Positive 70/100
Event
Market update
Published
08 Jul 2026 13:43
Source
Investing.com Canada
TradingView Direct company coverage

Price to earnings forward of Edgewise Therapeutics, Inc. – NASDAQ:EWTX

The article focuses on the "Price to earnings forward" metric for Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a biotechnology company. It presents a specific value for this metric and its associated change and percentage change, indicating these data points were "Made by humans."

Tone
Neutral 50/100
Event
Earnings
Published
08 Jul 2026 10:40
Source
TradingView
Stock Traders Daily Direct company coverage

(EWTX) as a Liquidity Pulse for Institutional Tactics

This article analyzes Edgewise Therapeutics Inc. (NASDAQ: EWTX) for institutional strategies, highlighting a mid-channel oscillation pattern and a significant 38.8:1 risk-reward setup targeting an 11.1% gain. It presents three distinct AI-generated trading strategies—Position, Mo

Tone
Positive 71/100
Event
Balance sheet
Published
07 Jul 2026 06:08
Source
Stock Traders Daily
Investing.com Direct company coverage

Guggenheim raises Edgewise Therapeutics stock price target on Servier deal

Guggenheim raised its price target for Edgewise Therapeutics (NASDAQ:EWTX) to $51 from $41, maintaining a Buy rating after the planned sale of Edgewise's muscular dystrophy business unit to Servier for up to $2.65 billion. The upgrade was also supported by positive Phase 2 CIRRUS

Tone
Positive 72/100
Event
Analyst action
Published
06 Jul 2026 14:10
Source
Investing.com
Investing.com Canada Direct company coverage

Guggenheim raises Edgewise Therapeutics stock price target on Servier deal By Investing.com

Guggenheim has increased its price target for Edgewise Therapeutics (EWTX) to $51 from $41, maintaining a Buy rating, following the planned sale of Edgewise's muscular dystrophy unit to Servier for up to $2.65 billion. The firm also cited strong efficacy data for EDG-7500 in hype

Tone
Positive 82/100
Event
Analyst action
Published
06 Jul 2026 13:09
Source
Investing.com Canada
Stock Titan Direct company coverage

If You Invested $1,000 in Edgewise Therapeutics, Inc. (EWTX)

This article analyzes the historical performance of Edgewise Therapeutics, Inc. (EWTX) stock, detailing potential returns for $1,000 investments made one, five, and ten years ago, as well as since its IPO. It further provides an in-depth company overview, highlighting its focus o

Tone
Positive 82/100
Event
Market update
Published
04 Jul 2026 13:39
Source
Stock Titan
Finviz Direct company coverage

EWTX - Edgewise Therapeutics Inc Earnings

This article provides a comprehensive financial overview of Edgewise Therapeutics Inc (EWTX), detailing its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It includes data on market capitalization, income, sales, EPS, a

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 00:42
Source
Finviz
Investing.com Canada Direct company coverage

Form 4 Edgewise Therapeutics Inc For: 2 July By Investing.com

This article announces the filing of Form 4 for Edgewise Therapeutics Inc. on July 2. Form 4 filings typically report changes in beneficial ownership of company securities by insiders. The article includes the company's stock symbol EWTX and notes a recent gain of 1.05%.

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:42
Source
Investing.com Canada
Stock Titan Direct company coverage

Edgewise Therapeutics (EWTX) CSO exercises 200K options and sells 200K shares

Edgewise Therapeutics' Chief Scientific Officer, Alan J. Russell, executed an exercise-and-sell transaction involving 200,000 shares of company stock. He exercised options to acquire 69,648 shares at $0.18 and 130,352 shares at $0.45, then simultaneously sold all 200,000 shares a

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:42
Source
Stock Titan